biotech / news / / The Manila Times
Results in a population of 278 patients affirm statistically significant mortality reductions.Benefits observed across severity groups and in subjects with serious comorbidities.
Paridiprubart's Phase 3 data showed a 27% relative reduction in 28-day mortality across 278 patients.
KEY POINTS
- Mortality reduction benefits with paridiprubart were observed in less severe ARDS and key comorbidity subgroups.
- Edesa Biotech has filed provisional patent applications for paridiprubart's use in sepsis, AKI, and pneumonia.
- Paridiprubart's safety profile remained favorable with low adverse event rates in over 400 treated patients.
- Edesa is evaluating strategic collaborations to accelerate late-stage development and commercialization of paridiprubart.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →